Genovac is a contract research and manufacturing organization offering advanced antibody discovery, development, and biologic production solutions. Genovac’s proprietary immunization technologies, combined with multiple single cell screening technologies, including Bruker Beacon, enable success against the most challenging targets. Since its founding in 1999, Genovac has completed more than 3,700 projects, providing therapeutic antibody drug candidates to clients in North America, Europe, Australia, and Asia. Headquartered in Fargo, North Dakota, Genovac operates discovery and production facilities in Fargo and Freiburg, Germany.